Inicio Castellano Catal Inicio
Título / ¿Más vale tarde que nunca?
Boletín: Boletín 8
Sección: Caso clínico
Autor/es:
Más información:
vv9v8v09fq:Noticias:{00501CDA-875F-4784-8603-DDD23;{0077D664-753A-47EE-B7A8-9E1E6;{0114F7B5-3DAE-4C06-BA71-D8610;{013AE826-8EB1-4D9D-B5D1-34996;{0181B92D-452B-4F67-AFD0-1075E;{0181D474-A65E-4237-9C14-F5131;{01E6188C-C121-420C-886C-A6AA0;{021CD9EB-2B4A-4F89-A4AF-EB8A8;{0232D7E7-5753-41A6-90B9-467A5;{0250D914-CE6C-429F-8D50-14361;{02AD62BE-E80A-499B-936B-D17FB;{02F8B7A2-6EC4-4EEB-9839-15EF8;{0346DC5A-CA5F-4DA0-88FF-2E34E;{037440BE-7F6C-47EC-BEC3-EEC96;{04076575-38ED-4421-B3CE-A80FF;{050BF388-704D-4982-87F0-1EE3A;{0598BD87-5E31-4F8D-9D48-9A1ED;{05AB0AAC-E063-48D6-974C-A49B1;{0653F0B4-7097-425E-B3CA-1AE57;{06FEC7F4-BCCC-4850-8BD3-62E22;{0849DD43-29CB-42FE-A40B-79690;{0909E6A3-2E44-4845-B595-07E6B;{090C593B-8AB2-416F-8470-1E2E7;{0940A141-C6C3-4628-B26E-7D60C;{09A731FC-37BB-459E-82D1-403EC;{0A587D45-1866-45FF-B707-CE94F;{0B3271B5-A2ED-4AF1-86DC-B8F86;{0B59DB10-0936-4FEE-B80A-E8C4E;{0C168F62-A059-4CE1-9203-BAAEC;{0DA98DF3-F8FE-4502-B5F9-14906;{0E8E51FD-DB25-4445-AA74-72971;{0F090068-0576-4084-A13E-F3CF2;{0FB8B041-4BA4-4401-B195-5BADF;{0FD5D736-2A56-45B9-BC70-76FED;{10CC4BF6-424C-45E2-8A62-7C6E9;{123497C8-5C22-4F58-AFD8-7662C;{12C8F999-865F-4766-B130-0385B;{13B46B39-6017-422A-999E-511FA;{13DDD49C-9DE2-4958-8A17-95E75;{13E00C05-E638-4E38-8C46-3C480;{13FD7008-6C47-4D90-B0AA-29824;{14CC70BA-4E1C-4FE2-98D8-4DA4C;{15649EA1-1D04-4B8D-B0B6-5019B;{177EF6DE-C1CE-470D-855E-F84BB;{1840CA23-CE64-4584-A002-33CB0;{185C5EF2-A6FC-4C1F-913B-AE510;{18AB8C27-17C6-43A2-B0B8-801D4;{18C10D42-8B5E-4FF4-8ADF-C4BD4;{19A40122-7BCF-4CC5-A254-DC6A2;{19BF7B31-C070-4B83-9F62-53205;{1AEBCDF8-1588-457C-8C4F-A3F24;{1BDDEA51-D5F6-4959-8420-D73ED;{1BE66390-EA19-4105-9009-E9021;{1C0D4C48-8FC1-499E-A50F-8DF9A;{1C825018-6FEE-4E65-AEC2-E7700;{1D1D1AF0-2468-4DFB-819F-90F8F;{1D30A54D-D2B7-4E35-BE13-34BCF;{1D6DB746-5CCD-4399-9CE6-03029;{1E047B5F-1EC0-480F-81EB-07804;{1EB7AE20-FFFC-4131-9D73-F97FE;{1ED087D5-E5AB-461D-8D47-CBF1E;{1F040168-E6D1-4282-B5F6-5741A;{1F57C140-4C75-4555-86E4-D3A04;{1F807FC7-ACF2-4045-AFE0-65300;{1FF043B0-DF77-42F8-AFF9-B503D;{202D925B-E486-46A6-A682-CA35D;{20354CD0-D28F-4DEB-8BC2-10EAD;{20851B08-2BA1-4917-B3AB-4A008;{223F235E-CE21-4988-AE07-A3CB5;{22DF6F42-7467-49E9-AD9D-A717B;{22ED388D-F36D-4EAC-9FF8-D440A;{22FC675F-F089-454D-9E07-0F552;{231E2D23-D1E1-4DD3-A843-4E653;{232A3628-B016-4836-8B52-85018;{2346F667-E976-443C-A63B-BED63;{23553058-51A8-496C-A102-CC199;{2370D803-2B78-4AD7-9600-D00E4;{245872A6-9027-442D-A910-FF152;{2610253A-9B70-4741-8249-96239;{26C223C1-3520-424B-A283-75792;{26C710A7-FD00-41A7-8DBF-F9697;{27040DDC-4F36-43C8-99A2-BCC3F;{27378F7B-BC1C-4881-8E4D-06B97;{273BDAC3-62A9-4703-B270-595A2;{278A9367-D5E7-4358-9C2A-E06F2;{27ACE821-6EEF-4466-9368-F4F7E;{27B8EA30-F469-4320-9AD9-A66DF;{2828E239-FC27-467C-A107-BB8F1;{28C299E3-5CB2-4CEC-B0F4-B91C1;{28D66DAB-CBFD-4D4F-955A-A2AB9;{291BFB26-2126-433B-9CB2-B9A0C;{298D2742-A322-4F4F-A97A-5F769;{2B3FF1A0-C67C-4D40-ACFE-57F41;{2B6C571B-C88B-4D30-8A65-24D24;{2BF70B25-8079-4E70-BAFB-9E0DF;{2C1779C5-DED2-4F4B-8EDB-EF10A;{2C6BC665-78F2-432E-9A50-49BF4;{2CB3F223-EC74-4804-9D79-ACD88;{2DE6F581-5252-4A5C-8AE2-456BB;{2F1BD084-7F50-44B9-840C-92AE9;{2F358C64-C6DA-4EF8-9065-3F4B2;{2F7C57B8-92AD-4436-B911-54AEF;{2F911F49-C507-4B74-A9D6-C0B48;{2F9641FB-B218-4755-AC2C-78410;{2FB95B8E-D351-4E12-9F1B-F1710;{302D9365-C9E6-4AF1-A46A-3471B;{31557084-3D38-4DDF-AF7A-1FBF5;{328BA9C4-D36E-4C67-8AFD-94C2D;{332B826B-97DD-4B67-AE16-31161;{339E91EF-894C-4780-9B53-4BCCF;{3413A36B-0A0D-451C-A54A-8AB04;{34323F81-14A7-42AC-AEA8-E96EB;{34F8856E-C99A-4DF3-B79A-E6EEB;{3531ECDB-0B69-423D-839D-D5E18;{362E4DF8-E183-470B-8BEF-D29C5;{374D20B9-8535-4CC3-ABB5-65B36;{3834DB82-60DE-46E3-862C-25F7D;{39DF7DE8-94D7-48E8-8876-63777;{3AC36854-C285-47C3-B98D-9951A;{3B640B81-E29D-4841-875F-298C7;{3B9E26B9-A006-48E0-9A04-C772D;{3BA3B139-BBDB-40F4-9753-7A3FA;{3BD0D55F-AC9F-486D-A3A4-93DAD;{3C07D98E-457C-4221-B685-6EBD6;{3C36C712-51F0-4FFF-B384-6D86B;{3EBAEB60-CCFA-449B-85B2-BF7F3;{3EFDE474-35E8-4D17-AE7C-E6636;{3F1C008D-CD94-4C93-A030-D972D;{3FEA94BC-D28C-4480-B591-F8534;{40329241-C008-4DF0-95E2-E4116;{405036E0-D23E-4C1F-83BA-A0401;{40F8EAE4-F3AE-4639-874B-616A7;{419CBAF8-EFF0-49BE-AC50-10024;{41BD8233-C61A-4022-9016-7CCDB;{422622B6-EA36-417B-A865-9F942;{425E088A-307D-4E5D-8555-419E9;{4299521C-5180-474A-AA77-896BC;{429B6A3B-CB1B-4BF3-91D7-F53FC;{431BBBEC-339E-4CAB-B812-AC955;{4451E1A7-C8B8-49FC-AB8B-1A91C;{44835683-31CD-4302-8CAE-B153D;{45966ADE-83BD-41CE-9830-8539D;{4632969F-EB27-4709-81CF-B2C9B;{474B9002-649D-4B17-9FFC-6F6A6;{47B79937-E32A-4694-A718-48C08;{47DF2ED3-9025-4532-BCFE-56A24;{48797932-E651-46AC-83F7-D161E;{48DE45E5-200A-4B8E-BFE9-8E302;{49D80916-4861-47AD-A28A-988E5;{4A1950F4-BBB2-4470-9960-333BC;{4AACD1CE-D882-4395-B1D0-84768;{4AE0C215-A6D0-44DD-8163-36140;{4C158D4E-F889-4029-8AFE-4E8A7;{4C2498D4-8070-4C29-AB07-D2E1B;{4C3B09B4-6B0A-4094-B9B0-63F9C;{4C919D53-00A0-4009-AB69-D70CC;{4CA1F3D9-BF21-4F74-AB08-B881F;{4CA7D78D-E2A1-4BAB-9344-A7F65;{4CACBA10-B0B1-495F-8639-45492;{4CBFBF32-4503-4F58-A23D-54689;{4CDE4AF7-248A-4DB0-8115-24979;{4D3E9E60-9D02-4E46-BC45-87D82;{4D4CA7A4-9B5D-46B8-8B6B-06F11;{4D67A7DC-54BB-43EC-B4A6-0222B;{4DAA3002-A584-4933-9994-EA34D;{4FD1F5E4-FF43-4AD4-8D5A-25D14;{501674FE-147F-4BB6-84B5-84D26;{5079D6AD-A2CB-4CEA-9992-D435C;{51559493-0EF9-4139-B961-E4CD0;{51D37EAD-D5B4-436D-B04C-0DF3F;{51EFCCBC-09DC-4CCB-A6B0-39F69;{52CABACC-F9B0-49E7-81FA-6D645;{5314218E-DE9E-4A50-B0ED-468F8;{5461765A-6DBE-4033-A4FA-625BF;{54811F79-F932-404A-B0EB-F131C;{54E7C8E3-DDF7-4FA2-9F66-29935;{554BBFBD-DD68-4901-B895-56559;{55F2A087-1AB8-49F1-BE24-5A5FC;{56613231-6CF3-41F7-B8EF-10813;{566F96F9-14A6-4B31-866E-EEE73;{571E0F15-A521-4D9B-A0B9-BD134;{5753EC55-99E3-43DE-88DF-AFAAB;{57D2F9FE-686D-483A-9BBD-6F032;{57EF2A6D-C77D-49F6-9C91-8D31B;{5828A65D-F9CB-4F82-A413-02173;{5877372F-3742-45FD-A308-A8408;{58FBBBC9-F520-4708-BE2A-445CF;{5932146A-4BAD-437B-A779-31AC1;{5A029511-3985-45FB-B87F-47FA6;{5A50E88D-8FE6-4523-A653-6F275;{5AB17FC0-063B-4121-B81F-2EB36;{5B0E87CB-F8F3-46F5-988B-FB5CB;{5BF3C36F-50B1-432F-B9B8-2067F;{5CD08FE7-68D3-41C0-8426-98D9A;{5D8A9049-3800-47DB-A787-820D5;{5E9BDFCA-0A83-4789-B4E7-F9EFA;{5EE8F312-515C-452E-A8DC-BE532;{5EF8F5D5-F381-4AB0-941E-96549;{5FA0DF5E-F0B3-4A59-8721-32168;{6041F440-708D-48D5-8418-6BC62;{611D691A-66C8-40F2-A7A4-BC628;{619811CC-49ED-49AE-B5A6-F0621;{627552B0-9D9D-4487-AFD0-0E219;{6317E952-5AD9-4898-9CE5-C5333;{63E312DE-7497-45E5-BCF6-A6B47;{63EC4C7A-4613-494A-9606-4B38E;{642B3645-8F53-4200-9E13-BCD1D;{6439903F-548C-4299-A7AB-8E43F;{64C4573B-3E34-4510-9C56-C6BED;{64DA9D4E-4E49-440F-9AD9-F1E04;{6530DF27-5F18-42EC-A9C3-C74F6;{6544D199-1D45-445E-8543-D721D;{65C08145-6E1E-4E61-8DEC-7AAF0;{662B3633-2F73-4D65-863C-12241;{66560730-39BF-4F5C-8E4D-7E20F;{66795696-9F6B-46F1-A546-60D3F;{6804CE42-1447-499C-81EA-8F23A;{687FC412-6B9C-4C05-9EA7-CD05D;{68B12F61-975D-49D3-A3D9-0A1E2;{69B00F2A-6182-4833-81CE-491C4;{69B49746-5B66-4679-AECE-325D3;{6A46682B-27DA-4E84-83EA-14F39;{6B346D91-FCBC-46A5-A025-86F17;{6B40D79E-A961-45E4-9FB8-5B786;{6B670F5F-1F65-4067-BB22-8C2F4;{6CD08D1B-05ED-4B90-B38D-E8277;{6E222BC6-713B-484A-9E7E-28545;{6F135543-08AC-421C-99CC-6FEA2;{6F4A9C2B-3941-4B54-A230-BF80D;{6F77B79A-55A5-4AC3-8435-CA12B;{6FF1D166-4370-438B-B6B0-8E017;{70496551-A4A0-4C5F-AA29-BACF7;{721D42CD-8253-4500-8B5C-AE982;{72E4BB39-FFF8-49FB-B391-0B52E;{72F07D48-41D3-4E27-93F1-B29B6;{733655FE-ABF3-45CB-82C0-8859D;{73C6AEC4-7C1F-4C96-910D-B5A17;{74201EEC-75DF-4B34-95F9-63659;{74BC7DA7-6B5E-4D58-A4B1-B957E;{74D50147-91AA-4B92-9192-C096B;{7522E8F8-08C8-4B81-A77D-4F00D;{766BB438-350A-44E5-BEB4-661CB;{76E68141-B972-4F45-BA29-EC73F;{76FD81D5-9E11-4FEF-B35F-DA3A1;{77588118-05E6-41C2-A5C7-59AF9;{785BD25E-4954-47FB-977C-9FC33;{786FFFA2-6386-4547-B2AD-52D9C;{78A4E8C8-219A-4F6F-84CE-E166F;{7949A030-CC96-49DB-B54F-DEF33;{7A629C86-B213-481D-94EA-D7077;{7A7BCA72-83A5-4437-B2FA-49E83;{7BB4ACFC-10E5-4F65-9459-B561D;{7BF9B4A9-6B9F-4731-9D65-1D4DB;{7C3C53C8-6A0C-4901-BAA3-C0867;{7C5CE69B-60EA-4B0A-89D4-3607D;{7D076E12-A619-455D-B44F-54FE3;{7D50B7A7-5A1E-4F0
Ver/Descargar PDF

 Paciente varón, 65 años, usuario habitual de la Unidad de Factores de Riesgo Cardiovascular con los siguientes antecedentes: cardiopatía isquémica en 1988, ateromatosis obliterante aortoiliaca en 1990 y isquemia bilateral EEII grado II6 con bypass aórtico en 1991. En 1999, se diagnostica trastorno afectivo orgánico secundario a un problema médico. En 1999, leve deterioro cognitivo asociado del 14%. En 2001, posible pseudodemencia depresiva. En 2002, demencia frontotemporal. 

Respecto al hábito tabáquico, fumador de 17 “puritos” al día, con escasa motivación para dejar de fumar. Cooximetría de 32 ppm. Propuesta de tratamiento utilizando diversas estrategias sin resultado, principalmente por falta de cumplimiento. En la última visita médica, se le avisa del elevado riesgo de posible amputación de una pierna. Ante la radiografía, jura no volver a fumar nunca más. 

Cooximetría de valoración a los quince días de 4 ppm.